AtriCure, Inc. (ATRC) has a negative trailing P/E of -115.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 392.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.86%, forward earnings yield 0.26%. PEG 4.20.
Criteria proven by this page:
Overall SharesGrow Score: 62/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -18.6 | -2.25 | 3.67 | 3.99 | - |
| 2017 | -22.0 | 1.05 | 3.67 | 3.38 | - |
| 2018 | -49.3 | 1.95 | 4.18 | 5.17 | - |
| 2019 | -34.7 | -0.67 | 4.94 | 5.29 | - |
| 2020 | -48.7 | -2.29 | 5.69 | 11.35 | - |
| 2021 | 62.4 | -0.32 | 6.48 | 11.42 | - |
| 2022 | -43.7 | 0.23 | 4.44 | 6.14 | - |
| 2023 | -54.3 | 1.54 | 3.55 | 4.14 | - |
| 2024 | -32.1 | -0.73 | 3.11 | 3.08 | - |
| 2025 | -165.0 | 2.21 | 3.84 | 3.53 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.05 | $155.11M | $-33.34M | -21.5% |
| 2017 | $-0.83 | $174.72M | $-26.89M | -15.4% |
| 2018 | $-0.62 | $201.63M | $-21.14M | -10.5% |
| 2019 | $-0.94 | $230.81M | $-35.19M | -15.2% |
| 2020 | $-1.14 | $206.53M | $-48.16M | -23.3% |
| 2021 | $1.09 | $274.33M | $50.2M | 18.3% |
| 2022 | $-1.02 | $330.38M | $-46.47M | -14.1% |
| 2023 | $-0.66 | $399.25M | $-30.44M | -7.6% |
| 2024 | $-0.95 | $465.31M | $-44.7M | -9.6% |
| 2025 | $-0.24 | $534.53M | $-11.45M | -2.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.05 | $0.01 – $0.07 | $603.19M | $601.94M – $604.18M | 7 |
| 2027 | $0.32 | $0.25 – $0.43 | $677.68M | $666.37M – $682.43M | 7 |
| 2028 | $0.60 | $0.41 – $0.78 | $766.73M | $766.69M – $766.77M | 4 |
| 2029 | $0.73 | $0.72 – $0.74 | $856.7M | $848.15M – $862.63M | 2 |
| 2030 | $1.05 | $1.04 – $1.06 | $986.5M | $976.66M – $993.33M | 2 |
